Literature DB >> 4268885

The excretion and degradation of chondroitin 4-sulphate administered to guinea pigs as free chondroitin sulphate and as proteoglycan.

P A Revell, H Muir.   

Abstract

The excretion and degradation was studied of (35)S-labelled 4-chondroitin sulphate injected into guinea pigs in the form of proteoglycan isolated from cartilage and in the form of free chondroitin 4-sulphate prepared from the same proteoglycan by proteolysis. When the proteoglycan was injected there was a delay of about 15-20min before significant amounts or radioactivity were excreted, whereas after injection of chondroitin 4-sulphate a considerable amount of radioactivity was excreted within 10min and a much higher proportion of the radioactive dose was excreted in 1h or 24h compared with the proteoglycan. In both cases, however, a major part of the radioactivity was not excreted even in 24h. Sterile conditions were used to collect the radioactive material directly from the bladder. When chondroitin 4-sulphate was injected, the molecular sizes of injected and excreted materials were similar, as assessed by gel chromatography on Sephadex G-200, whereas when proteoglycan was injected the molecular size of the excreted labelled material was similar to that of the chondroitin 4-sulphate chains in the original proteoglycan. In neither case did the size of the excreted labelled material change with time over 1h, and low-molecular-weight labelled material was virtually absent. In contrast, when urine was collected for 24h without preservative the labelled material in it was extensively degraded after either the proteoglycan or chondroitin 4-sulphate had been given. Chondroitin 4-sulphate became similarly degraded when incubated with non-sterile urine, but not when the urine was passed through a bacterial filter, suggesting that degradation was caused by contaminating micro-organisms in the experiments in which urine was collected for 24 h. It is concluded that chondroitin 4-sulphate chains of about 18000 molecular weight can be excreted readily as such, whereas intact proteoglycans must be degraded to free glycosaminoglycans first, although both are taken up by the tissues more rapidly than they are excreted.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4268885      PMCID: PMC1174440          DOI: 10.1042/bj1300597

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  The defect in Hurler's and Hunter's syndromes: faulty degradation of mucopolysaccharide.

Authors:  J C Fratantoni; C W Hall; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1968-06       Impact factor: 11.205

2.  Structural studies on heparitin sulfate of normal and Hurler tissues.

Authors:  J Knecht; J A Cifonelli; A Dorfman
Journal:  J Biol Chem       Date:  1967-10-25       Impact factor: 5.157

3.  Biochemical heterogeneity of the Sanfilippo syndrome: preliminary characterization of two deficient factors.

Authors:  H Kresse; U Wiesmann; M Cantz; C W Hall; E F Neufeld
Journal:  Biochem Biophys Res Commun       Date:  1971-03-05       Impact factor: 3.575

4.  The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation.

Authors:  J C Fratantoni; C W Hall; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1969-09       Impact factor: 11.205

Review 5.  An essay on the biology of osteoarthritis.

Authors:  A J Bollet
Journal:  Arthritis Rheum       Date:  1969-04

6.  Specific inhibition of cartilage breakdown.

Authors:  P D Weston; A J Barrett; J T Dingle
Journal:  Nature       Date:  1969-04-19       Impact factor: 49.962

7.  A method for the determination of molecular weight dispersion in chondroitin sulphate on a microgram level.

Authors:  A Wasteson
Journal:  Biochim Biophys Acta       Date:  1969-02-18

8.  L-iduronidase in cultured human fibroblasts and liver.

Authors:  R Matalon; J A Cifonelli; A Dorfman
Journal:  Biochem Biophys Res Commun       Date:  1971-01-22       Impact factor: 3.575

9.  Hurler's, Hunter's and Morquio's syndromes. A biochemical study in the light of current views of the underlying defects.

Authors:  M F Dean; H Muir; R J Ewins
Journal:  Biochem J       Date:  1971-08       Impact factor: 3.857

10.  The tissue content and turnover rates of intermediates in the biosynthesis of glycosaminoglycans in young rat skin.

Authors:  T E Hardingham; C F Phelps
Journal:  Biochem J       Date:  1968-06       Impact factor: 3.857

View more
  7 in total

1.  Mechanism of action of intradiscal chymopapain in the treatment of sciatica: a clinical, biochemical, and radiological study.

Authors:  J R Jenner; D J Buttle; A K Dixon
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

2.  Tissue uptake of circulating hyaluronic acid. A whole body autoradiographic study.

Authors:  J R Fraser; L E Appelgren; T C Laurent
Journal:  Cell Tissue Res       Date:  1983       Impact factor: 5.249

3.  The degradation of intravenously injected chondroitin 4-sulphate in the rat.

Authors:  K M Wood; F S Wusteman; C G Curtis
Journal:  Biochem J       Date:  1973-08       Impact factor: 3.857

4.  Inhibition of hyaluronan uptake in lymphatic tissue by chondroitin sulphate proteoglycan.

Authors:  C Tzaicos; J R Fraser; E Tsotsis; W G Kimpton
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

5.  Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit.

Authors:  J R Fraser; T C Laurent; H Pertoft; E Baxter
Journal:  Biochem J       Date:  1981-11-15       Impact factor: 3.857

6.  Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate.

Authors:  A Baici; D Hörler; B Moser; H O Hofer; K Fehr; F J Wagenhäuser
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

7.  The metabolic fate of intravenously injected peptide-bound chondroitin sulphate in the rat.

Authors:  K M Wood; C G Curtis; G M Powell; F S Wusteman
Journal:  Biochem J       Date:  1976-07-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.